Compound Evidence File
#EC-2026-0711
Cagrilintide
Filed under Peptides. The bureau holds 137 laboratory returns for this compound from 34 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
34 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 2 Dec 2025 | 28 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 10.0 | 10.0 | 2 Mar 2026 | 12 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 22 May 2026 | 21 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 9 Jun 2026 | 5 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 10.0 | 10.0 | 13 May 2026 | 5 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 1 Mar 2026 | 27 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 10.0 | 10.0 | 10.0 | 12 May 2026 | 13 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 10.0 | 10.0 | 10.0 | 14 Nov 2025 | 4 Jul 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 5 | 9.9 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 27 Mar 2026 | 5 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 15 Apr 2026 | 13 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 9 Apr 2026 | 2 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 6 Jan 2026 | 4 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 9.9 | 9.9 | 9.9 | 18 Feb 2026 | 10 Jul 2026 |
| UtherCASE #VI-2026-0902 | A | 2 | 9.1 | 8.5 | 9.8 | 9 Oct 2025 | 9 Oct 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 5 | 8.7 | 7.0 | 9.4 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.7 | 7.6 | 9.7 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 8.3 | 7.6 | 9.1 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 8.2 | 6.6 | 9.1 | 25 May 2026 | 25 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 7.5 | 6.5 | 8.5 | 23 May 2026 | 23 May 2026 |
| Anlv BiotechnologyCASE #VI-2026-0110 | X | 1 | 7.4 | 7.4 | 7.4 | 25 May 2026 | 25 May 2026 |
| NexaphCASE #VI-2026-0944 | B | 10 | 7.2 | 5.3 | 9.3 | 14 Jun 2025 | 21 May 2026 |
| Reta-PeptideCASE #VI-2026-0756 | B | 3 | 7.0 | 6.1 | 8.0 | 1 Jul 2025 | 4 Sep 2025 |
| Qing Li PeptideCASE #VI-2026-0469 | C | 3 | 7.0 | 5.0 | 9.7 | 9 Jul 2025 | 11 Dec 2025 |
| Yiwu Aozuo Trading CoCASE #VI-2026-0798 | C | 6 | 6.9 | 4.8 | 8.0 | 28 Jun 2025 | 15 Jan 2026 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | B | 2 | 6.5 | 6.5 | 6.6 | 14 Jul 2025 | 14 Jul 2025 |
| HXNetCASE #VI-2026-0061 | E | 10 | 6.2 | 2.8 | 8.3 | 17 Nov 2025 | 23 May 2026 |
| Peptide-SCASE #VI-2026-0111 | C | 4 | 6.1 | 4.7 | 6.9 | 14 Jun 2025 | 25 Nov 2025 |
| HK PeptidesCASE #VI-2026-0140 | C | 7 | 5.9 | 4.3 | 9.7 | 16 Aug 2025 | 24 May 2026 |
| SRY LabsCASE #VI-2026-0657 | D | 6 | 5.5 | 3.5 | 7.2 | 20 Apr 2025 | 17 May 2026 |
| TSC Top Supplements ChinaCASE #VI-2026-0523 | D | 5 | 5.5 | 3.4 | 8.0 | 9 Jul 2025 | 21 May 2026 |
| PeptiSlimCASE #VI-2026-0557 | X | 1 | 5.4 | 5.4 | 5.4 | 25 May 2026 | 25 May 2026 |
| Shenzhen Loga Tech LG LOGACASE #VI-2026-0920 | X | 1 | 4.2 | 4.2 | 4.2 | 9 Jul 2025 | 9 Jul 2025 |
Open any subject to view the batch-level evidence for Cagrilintide alone.